In vivo purging with Rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (PTS).

被引：0
|
作者：
Salles, G [1 ]
Moullet, I [1 ]
Charlot, C [1 ]
Thieblemont, C [1 ]
Bouafia, F [1 ]
Dumontet, C [1 ]
Espinouse, D [1 ]
Coiffier, B [1 ]
机构：
[1] Ctr Hosp Lyon Sud, Hematol Serv, F-69310 Pierre Benite, France
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
619
引用
收藏
页码：141A / 141A
页数：1
相关论文
共 50 条
  • [41] Peripheral blood progenitor cells (PBPC) mobilized at the time of haematopoietic reconstitution after autologous transplantation.
    Koza, V
    Jindra, P
    Lysák, D
    Skopek, P
    Cetkovsky, P
    BONE MARROW TRANSPLANTATION, 1999, 23 : S203 - S203
  • [42] High efficacy and good tolerability with rituximab in vivo purging followed by high dose chemotheraphy and autologous peripheral blood stem cell transplantation (APBSCT) in non-Hodgkin's lymphoma (NHL).
    Shi, YK
    Yang, S
    Han, XH
    Liu, P
    He, XH
    Ma, J
    Ren, HY
    Cen, X
    Zhou, SY
    Wang, C
    BLOOD, 2004, 104 (11) : 240B - 240B
  • [43] In vivo plus ex vivo purging during autologous peripheral blood stem cell transplantation in high-grade B cell non-Hodgkin's lymphoma
    Arpaci, F.
    Erdem, G.
    Ataergin, S.
    Cetin, T.
    Ozturk, M.
    Kuzhan, O.
    Komurcu, S.
    Ozet, A.
    Cayakar, A.
    Eren, O.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S346 - S346
  • [44] Outcome and factors associated with slow mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing autologous transplantation for non-Hodgkin's lymphoma (NHL).
    Bociek, RG
    Lynch, JC
    Yee, GC
    Bierman, PJ
    Vose, JM
    Armitage, JO
    Brannan, RL
    Petersen, KA
    Kessinger, A
    BLOOD, 2001, 98 (11) : 861A - 861A
  • [45] EARLY HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION IN PATIENTS WITH HIGH-RISK, AGGRESSIVE NON-HODGKINS-LYMPHOMA
    BRUGGER, W
    GRAMATZKI, M
    KOLLMANNSBERGER, C
    KIEFER, T
    MERTELSMANN, R
    KANZ, L
    BLOOD, 1994, 84 (10) : A234 - A234
  • [46] Salvage chemotherapy and autologous peripheral blood progenitor cells transplantation in resistant lymphoma
    Sica, S
    Salutari, P
    Chiusolo, P
    DiMario, A
    Teofili, L
    Marra, R
    Micciulli, G
    LaBarbera, EO
    Leone, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 348 - 348
  • [47] Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC)
    Bredeson, C
    Malcolm, J
    Davis, M
    BenceBruckler, I
    Kearns, B
    Huebsch, L
    BONE MARROW TRANSPLANTATION, 1997, 20 (10) : 889 - 896
  • [48] Arterial blood oxygenation, maximum exercise capacity and oxygen transport in patients before and after autologous peripheral blood progenitor cell transplantation
    A Gruber
    T Brundin
    M Björkholm
    Bone Marrow Transplantation, 1999, 24 : 169 - 172
  • [49] Arterial blood oxygenation, maximum exercise capacity and oxygen transport in patients before and after autologous peripheral blood progenitor cell transplantation
    Gruber, A
    Brundin, T
    Björkholm, M
    BONE MARROW TRANSPLANTATION, 1999, 24 (02) : 169 - 172
  • [50] Favourable outcome of mantle cell lymphoma after autologous stem cell transplantation with in vivo or ex vivo purging
    Kuwatsuka, Y.
    Kato, H.
    Oki, Y.
    Taji, H.
    Yamamoto, K.
    Kagami, Y.
    Morishima, Y.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S255 - S256
12345